Voloridge Investment Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Voloridge Investment Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,559	Closed	-$258K	–	1778
2021 Q4	$258K	Buy	+14,559	New	+$279K	﹤0.01%	1489
2020 Q4	–	Sell	-10,328	Closed	-$164K	–	1633
2020 Q3	$164K	Sell	10,328 -12,265	-54%	-$224K	﹤0.01%	1201
2020 Q2	$446K	Buy	+22,593	New	+$432K	0.01%	1059
2020 Q1	–	Sell	-11,166	Closed	-$206K	–	1466
2019 Q4	$206K	Buy	+11,166	New	+$163K	﹤0.01%	997

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Voloridge Investment Management's NGM Position: Q1 2022 in Review

Voloridge Investment Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022, closing a stake of 14,559 shares — an estimated $258K sold.

Voloridge Investment Management first reported a position in NGM in Q4 2019 and held it in 4 quarters. The position peaked at $446K in Q2 2020. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

Voloridge Investment Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Voloridge Investment Management sold 14,559 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $258K.
Voloridge Investment Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
Voloridge Investment Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $446K in Q2 2020.
114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Voloridge Investment Management's 13F filing for Q1 2022, filed 16 May 2022.